[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-joint-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-joint-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100650590","improving-patient-centered-care-for-underserved-older-african-american-patients-with-cardiovascular-comorbidities-100650590",false,"NCT07748858","Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities","Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities: A Pilot Study of the Patient Priorities Care Approach at Cooper Green Mercy Health Services Authority (PPC-HEART)","PPC Heart","Inclusion Criteria:\n\n* greater than or equal to 50 years old\n* at least one CVD (i.e., coronary artery disease, hypertension, heart failure, arrhythmias, cardiomyopathy, peripheral artery disease, stroke, and valvular heart disease)\n* at least one coexisting chronic condition (i.e., inflammatory joint disease, COPD\u002Fasthma, diabetes, chronic kidney disease, and cancer one-year post-treatment)\n* a caregiver of a participant, or a provider who serves this population.\n\nExclusion Criteria:\n\n* Axis I psychiatric (schizophrenia, bipolar disorder), dementia, suicidal ideation,\n* active substance use disorder nursing home or assisted living facility residence.","ALL","50 Years","99 Years",{"count":21,"type":22},29,"ESTIMATED","OBSERVATIONAL","This is formative evaluation trial guided by the Values Clarification Theory25 and the Cultural Values Theory26, with specific aims to: Aim 1. Develop a culturally appropriate version of the PPC Approach for older AAs with CVCs by assembling a community advisory group of 3 primary care clinicians, 3 older AA patients with CVCs, and 3 AA persons who care for AA patients with CVCs to solicit feedback on the PPC Approach. Aim 2. Determine the acceptability (e.g., program appraisal interviews) and feasibility (e.g., avg. length of program sessions, program participation rate, study completion rate) of the PPC Approach among a sample 20 of under-resourced older southern AA patients with CVCs receiving primary care at Cooper Green Mercy Health Services Authority. Aim 3. Examine the ability of participants to complete pre- and post-test (8 weeks post-baseline) measures of perception of care, treatment burden, shared decision-making, and patient-clinician communication exchange.",[26,27,28,29,30,31,32],"Cardiovascular","Comorbidity","Diabetes","Inflammatory Joint Diseases","Chronic Kidney Diease","Chronic Obstructive Pulmonary Disease (COPD)","Cardiovascular Disease",[34,35,36,37,38,39,40,41],"Cardiovascular Diseases","Chronic Kidney Disease","Chronic Obstructive Pulmonary Disease","Patient-Centered Care","Shared Decision Making","Care Coordination","Older Adults","Multiple Chronic Conditions","RECRUITING","2026-07-31",{"date":45,"type":46},"2026-08-06","ACTUAL",{"date":48,"type":46},"2026-05-01",{"date":50,"type":22},"2027-06",{"name":52,"class":53},"University of Alabama at Birmingham","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":54},"100634195","oxidative-stress-in-autoimmune-rheumatic-diseases-100634195","NCT07536529","Oxidative Stress in Autoimmune Rheumatic Diseases","Investigation of the Role of Redox Status of Patients With Autoimmune Rheumatic Diseases on Disease Progression: An Epidemiological Study","REDOX-ARD","Inclusion Criteria:\n\n* Adult patients (\\>18 years old), with a primary diagnosis of rheumatoid arthritis using the criteria of American College of Rheumatology (ACR)\n* Adult patients (\\>18 years old), with a primary diagnosis of psoriatic arthritis using the ClASsification criteria for Psoriatic Arthritis (CASPAR)\n* Adult patients (\\>18 years old), with a primary diagnosis of alkylosing spondyloarthritis using the criteria of Assessment of SpondyloArthritis international Society (ASAS) group\n* Adult patients (\\>18 years old) irrespective of gender\n* Adult patients (\\>18 years old) irrespective of ethnicity\n* Adult patients (\\>18 years old) irrespective of comorbidities\n* Adult patients (\\>18 years old) irrespective of socioeconomic background\n* Adult patients (\\>18 years old) with any disease status\n* Adult patients (\\>18 years old) with any disease duration\n* Adult patients (\\>18 years old) under any treatment scheme (e.g. non-steroidal anti-inflammatory drugs, steroids, disease-modifying anti-rheumatic drugs including biologics)\n\nExclusion Criteria:\n\n* Adult patients (\\>18 years old) with concurrent infectious disease\n* Adult patients (\\>18 years old) in pregnancy\n* Patients under 18 years of age","18 Years",{"count":65,"type":22},200,"Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, Sjogren's syndrome and systemic scleroderma. These autoimmune disorders lead to joint destruction and adversely influence the human body systemically. One of their characteristics is comorbidity, since patients usually suffer also from other pathologies such as cardiovascular diseases and obesity. In addition, their treatment requires a combination of both biological and conventional pharmaceutical interventions as well as other parameters such as physical activity programs, nutrition, and the use of smart electronic devices. Therefore, the ARDs burden health systems worldwide. Apart from the physiological manifestations of ARDs, specific changes are observed at the cellular and molecular level. A common biochemical\u002Fmolecular symptom of these diseases is oxidative stress. This condition leads to the disturbance of blood and tissue redox status due to the excessive production of free radicals. Given that free radicals are highly reactive moieties with strong oxidative capacity against biomolecules (i.e., proteins, lipids, DNA), they compromise the efficacy of the intrinsic antioxidant mechanisms and, finally, induce the disruption of redox homeostasis. However, there is no sufficient data linking the levels of redox status of patients with the progression of ARDs over time. Indeed, the onset and symptoms of ARDs are intertwined with the disruption of the patient redox homeostasis and the induction of oxidative stress. Concurrently, the absence of a completely effective pharmaceutical treatment emerges the need for the adoption of novel biomarkers for monitoring the severity of the symptoms and the evolution of ARDs in general. To that end, this study aims at first to investigate the blood redox status of patients with ARDs. Thus, specific redox biomarkers will be evaluated in the blood of patients in three time points (i.e., at Days 1, 180 and 360), and they will be associated with the clinical manifestations of their diseases. The ultimate goal is to clarify whether these biomarkers could putatively exert clinical significance, namely whether they could constitute an additional tool for the monitoring of the progression of these diseases in clinical practice.",[29,68,69,70],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)",[72,73,74,75,76],"Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Oxidative stress","Antioxidants","2026-04-22",{"date":79,"type":46},"2026-04-28",{"date":81,"type":46},"2025-10-06",{"date":83,"type":22},"2026-10",{"name":85,"class":53},"University of Thessaly",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100177230","the-norwegian-antirheumatic-drug-register-100177230","NCT01581294","The Norwegian Antirheumatic Drug Register","Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study","NOR-DMARD","Inclusion Criteria:\n\n* Age \\>18 years\n* Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis\n* Clinical indication to start a new treatment with a biological disease modifying anti-rheumatic drug or a kinase inhibitor\n\nExclusion Criteria:\n\n* Unwillingness or unability to give written informed consent\n* Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible\n* Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study protocol",{"count":95,"type":22},15000,"NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.",[29],[72,73,74,99],"Spondyloarthritis","2022-08-19",{"date":102,"type":46},"2022-08-23",{"date":104,"type":4},"2012-04",{"date":106,"type":22},"2050-12",{"name":108,"class":53},"Diakonhjemmet Hospital",6]